Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A blood glucose level of equal to or greater than 180 mg/dL that occurred during stress in a patient without diabetes mellitus (DM) is termed stress hyperglycemia (SH). The stress hyperglycemia ratio (SHR) is defined as the fasting blood glucose divided by the blood glucose level that is calculated from the glycosylated hemoglobin (HBA1c) value on admission. A significantly higher SHR is associated with worse prognostic biomarkers in diabetic patients with complications
Stress hyperglycemia (SH) is an increase in circulating glucose levels in biological fluids as a physiological response to stress in diabetic patients who are known or newly diagnosed, or a pathological condition associated with in-hospital-related hyperglycemia.
Interventions. Through their pleiotropic effects, some oral hypoglycemic agents improved stress hyperglycemia. When compared to non-SGLT-I (sodium glucose transporter-inhibitor) users, diabetic patients who used (SGLT-I) and had an acute myocardial infarction had less prevalent stress hyperglycemia, a smaller infarct size, and evidence of a low inflammatory response. The rationale this study is to evaluate the SHR in T2D patients who do not have serious illnesses and are managed with oral hypoglycemic agents
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sitagliptin/metformin | Patients with T2D treated with sitagliptin/metformin (50/500mg) once daily for 10 weeks |
| |
| Empagliflozin/metformin | Patients with T2D treated with empagliflozin/metformin (10/500mg) once daily for 10 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sitagliptin/metformin ( 50/500mg) Oral Tablet | Drug | The drug was prescribed once daily per oral for 10 weeks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Stress hyperglycemia Ratio | The ratio of stress-to-on admission blood glucose was calculated | 10 week |
| Measure | Description | Time Frame |
|---|---|---|
| Hematological indices | Concentration of hemoglobin (g/dL) and the value of mean corpuscular volume (fL) | 10 week |
| Inflammatory markers | Concentration of c-reactive protein (mg/L) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Known cases of type 2 diabetes who were attending the diabetes centers and private clinics seeking for diabetes control and follow-up.
The authors discussed with the participants about the study design and outcomes
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ismail Latif | The Dean College of Medicine, University of Diyal | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| College of Medicine, University of Diyala | Baqubah | Diyala Governorate | 32001 | Iraq |
The data of this study can be shared on request
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068900 | Sitagliptin Phosphate |
| D008687 | Metformin |
| D013607 | Tablets |
| C570240 | empagliflozin |
| ID | Term |
|---|---|
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood samples
| Empagliflozin/metformin(10/500mg) Oral Tablet | Drug | The drug was prescribed once daily per oral for 10 weeks |
|
|
| 10 week |
| D004700 | Endocrine System Diseases |
| D011719 |
| Pyrazines |
| D001645 | Biguanides |
| D006146 | Guanidines |
| D000578 | Amidines |
| D009930 | Organic Chemicals |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |